Watch Ticker

IN8bio, Inc. Common Stock

Go to IN8bio, Inc. Common Stock Website

$2.17

0.08 (3.83%)

Live

Previous Close

$2.09

Day Range

$2.09 - $2.1799

Previous Day Range

$1.98 - $2.1

Market Cap

$7.3 million USD

Day Vol.

83324

Previous Day Vol.

127334

Currency

USD

Primary Exchange

Nasdaq

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio's gamma-delta T cell therapy INB-200 has demonstrated a significant clinical milestone, with a patient with a grade 4, IDH-mutant glioma remaining in remission and progression-free for 4 years after treatment. This outcome highlights the potential of INB-200 in treating this aggressive and deadly cancer.

Related tickers: INAB.

Read Full Article

In8Bio, Inc. - IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio reported positive Phase 1 data for its gamma-delta T cell therapy INB-100, with 100% of treated AML patients remaining relapse-free. The company also presented new preclinical data on its INB-600 gamma-delta T cell engager platform, which demonstrated strong antigen-specific cytotoxicity with potential applications in oncology and autoimmune diseases.

Related tickers: INAB.

Read Full Article

Trending Tickers

Please sign in to view